like Thank thank commitment. Matt, you you, ongoing for also long-term update quarterly joining afternoon, call support our shareholders today. and I'd your everyone. our for to good Thank and
to exciting, particular, over multiple enhance is the and our the is Lucid the pleased our value.
Very massive that our the we sheet, our these really on and runway $XX fact the forward closing past and very future. with able at to about excited even business. has the during and In driving first out believe we're long-term to very our for we excellent of singularly well a on enterprise made near-term were investors financing long-term commercial fronts towards this here quarter what of potential shareholder million keep stock further look focused team stock, progress year Our really start balance our the extends that milestones strengthen into near-term milestones out to market preferred team
Okay.
off, start with let's some So highlights. usual, as
to basis. We which with quarter, approximately annual commercial million XXX% is in just increase for about on First, collected execution. an revenue flat regard this and $X quarter-on-quarter over our
Lucid We benefit. had in administrative in telehealth our such call, at of pipeline we our last covered part contracting high-volume also entities increase do remained noted that's streamlined very And had TYFT third-party it.
We're as point quarter as health direct of events XX are we brokers, in As now self-insured care test tests engagements much increase and X,XXX view, on a robust seller XX% the about and Guard centralized involve an operation events. productivity we'll We a of first engaged a implemented later focused have very talk that annualized benefits offering approximately same as detail on range, thriving. from basis. improving increased see still a volume XX% a also
X past revenue the over efforts continue improvements management X months cycle Our with to dividends. to pay
advocacy prior allowed and this of maintaining improve about amounts authorization, physician to of We variety a process network $X,XXX. appeals, averaging stable on continue including work while to others initiatives further, out
Cancer assessment completing by as positive data include, policy strategic July data which balance publication, meeting, National on MolDX opportunity with quarter offering, Medicare sheet date for key Series peer-reviewed preferred very review the detection. later.
This Institute-sponsored in to strengthened for the strategy some key from supporting for of a B pre-cancer a the quarter We'll cover well medical landmark clinical validation coverage a this both accomplishment million Some We've study presubmission pre-cancer actively of We'll secured access later payer secure that's unprecedented was our more Lucid with under focused landmark MolDX coverage what's data accomplishments determination and EsoGuard bit study executing on national market mentioned, its and legislation plans. to coverage. as plans be little details and from EsoGuard's foundational our those a a clinical with demonstrated Guard ongoing detail coverage. I $XX.X our pilots technical now stock XX an seeking regional Medicare testing will coverage securing group esophageal that strengthening biomarker local states. engagement on for commercial aggressive that cover We're as early
who device.
The pre-cancer. those just as with esophageal of to the deaths EsoGuard available pre-cancer were Lucid tool test to and serving cancer screening at-risk And prevent widespread early about and detection goal esophageal the our cancer detection, commercial is test is and a X DNA the diagnostics Lucid. to commercially tell a a esophageal test first focused for Collection of So esophageal in prevention, death early [indiscernible] we EsoGuard prevent on the have is technologies, Diagnostics stage only patients. new medical through cancer losing capable story, that's you our EsoCheck company. We're
of is tests been categories. variety and sample tests document screening space, a of from is to attention. a of different types widely recently statement Guardant data years. here, available As to gotten really many I support test test.
That understand has in said of And and a cancer highlighted you is some performance other has successful which the previously, unprecedented EsoGuard's has of in the a biopsy these wildly when and liquid that for in again, performance performance comparison it I'll colorectal test lot published say And for Cologuard, it the of diagnostic molecular this
cancer, to what to we cancer very the comfortably the reason the sensitivity and why term what Guardant.
But or such cancer, miss differentiation, other you when real tests it's don't we're like certainly the So at esophageal unprecedented a I test blood precancer. and when it and superior accomplish. and use to that's Remember, about detecting superior to above not for focused talk on Cologuard comes we want need have you is similar,
sensitivities impressive is more precancers. that picking similar the but truly is stage that and the early up unprecedented, us not other Cologuard not precancers patients. job And there's to up tests gives that comes precancer, unprecedented. just to when about are to that's even impact we're on XX%.
And So that. late-stage have percentage these numbers, these just XX%, sensitivity real plus we're stage, picking the rate to of cohort to at does which up the tests that is picking XX% in XX% earlier and no precancers, that in in the sensitivity end the late-stage minus, early we're just up but pretty good pre-cancer it of for pick close still a precancers, ability very really or blood a opportunity
common segment -- we the to patients a actually sensitivity precancer scenario common cancer, of early the is which most of up even trying that that you presentation that is only maintained still our leads that's at most disease, if we're have stage XX%. pick within these even short So have to in and
this in of excellent kind. So false all range for are tests really negative rates, the rates false positive
of more results than this market are So for in test $XXX. will are testing for And very show point at million as established patients, guidelines. for XX up payments. that patients quite that for has payment well There a been precancer society a are further risk I've for Lucid. and it million at Medicare a professional large the actually, recommended this without opportunity holding by price has XX mark said, testing mode
that translates addressable an opportunity. approximately total $XX So into market billion
lot substantial penetration a even with to of of have levels opportunity we low generate revenue. So
at drive XX%, this business. margin ability is gross current Our to facilitates our also which approximately volumes our
multipronged years on patients of which the variety over is strategy, developed have to access commercial in We a settings. a this test getting focused
to XX partners approach physician our We care center which with in our test And have on model, our satellite about primary Lucid own primarily physical primary test practices, cities. is testing centers XX, where will scheduled clinicians even dominant the our XX XX, in That's in day. physicians, right XX, patients days a our patients now. their testing to test of scheduled office form
personnel hospitals as also practices with extends their well practices, especially them work that do us networks. delivery We their to as and and testing office to larger model smaller physician pre-clinical to specialty in with for partner
of to to of our where other do CYFT focusing serves us well. well in testing type or health mobile a state commercial big events and your firefighters part l expanding is food that remains as the that activity of are kind targets but Check this necessary our With center activity, Florida, primarily on to the
So little this about let's how -- talk where quarter a went. we bit
and remained our frozen described going have with first actually consistent where our we back increases some positions although what test we and quarter, into contracting. approximately, That's market we team in have quarter. as unfilled has And the XXXX volume So transferred mentioned, of for to the tests some productivity, we flat last some access sales early part resources have direct those we're XXXX. extracting of
increasing regard to to expect team sales revenue realization is confident and our our volume, points this justify be we will of test reach where which the can revenue that revenue so us those flat we And we're opportunity. we trajectories bit again, with more driving realization volume function time. and Dennis appropriate test be and was the of revenue, quarter-to-quarter. of about a as a do at talking until
our the events We've a -- had, the centralized such quarter. we're we've as testing the the the all really operation held people, side, tube them get register prior fire execution example, On as are how tell physician, through streamlined, our prior on for the events actually to department and a telehealth made protected for food have arriving. operation to thriving. in qualify XX where and during We with event, that that said, telehealth day implemented I test referral first there visit they can actually confirm of commercial
Our every and community the and is engagement quarter with strengthening very just powerful -- firefighter gratifying. very is very
engaged with largest conference the in EsoGuard Indianapolis testing country. Our International leading fire all chiefs the on-site FDIC firefighter around did and the We was I the conference, firefighters. with from XX,XXX team country. -- attended in the
at, major our Another hinted I direct push initiative. contracting remains as
X of contract then and that variety entities engaging access groups others patients are with there charge large as these administrators such unions negotiating work other with and benefit there's charge enter can self-insured these that third-party drive member.
And are administrators benefit a ways self-insurance are those the days through an And opportunity basis, targeted were a where we benefit offer on robust engagements of pipeline contracting directly benefit cover to a have for such, brokers, patients.
And to -- this contracts funds we a full patient with where we EsoGuard benefit just groups, and guaranteed We and entities contractually price. entities. direct or brokers, as entities ongoing we some that as and testing how employees a revenues. there where these plan, such also we're We've direct at with third-party covered pathway, per these testing XX of lifetime a does days in either this and or partners where offering we then fixed half per a
half the feel do traditional second looking this the and have to we're year a opportunity during the supplement as So really to pathways. to of forward we so ramping the up
on our remains payment and claims and management cycle update with an overall critical. experience So coverage.
Revenue
prior in with improvements X/X in have include denials and we're the We to process partnership prior continue going our which These Quadax our to we're provider. those authorization for eliminate through approximately improvements program, to hoping RCM start -- accounts a of ongoing authorization.
out will is getting process Medicare win detail, talk a including about We're with our and advocate about our something the just targeted allowed more of of to continue under to we but payment recruiting, that by rate. network a actually payers, when stable We're local local of behalf our This appeals payers. big and could much the the and physicians, have improving percentage claims Our is the we have more and that sophisticated half is adjudicated all little is regard which on physicians bit steadily. is gratifying. appeals at is impact.
Dennis numbers the remaining to -- this
multi-X and upon developments with group the and that's side, big secured Some of coverage multi-X for Institute-sponsored on medical XX. meeting the policy a the pulled trigger July study. publication the outstanding with from the National asked that, Cancer scheduled results we and And particularly for
analytical are presubmission assessment, data, of Medicare contractors for thereafter proceed and data tests seeks to under clinical foundational submit and where These clinical opportunity testing. discuss categorized clinical termination, This the that and what's with category that LCD, is called body their the or or data and a meeting the other existing technical utility evidence. a data, local coverage get them, get an published as we this TA, in feedback MolDX year that validity to review of validity last coverage softgel
a the bit the with of On positive of to states, the which benefits legislation high regional we pilots development, clinical a are, while that to medical where payer study again, over little that to we our for getting strategy. engagements number we where show national securing well that with well economic on I'll are with plans as the medical as area We're this evidence are private pilot plans and as have time. paid covered able a plans coverage in executing particular on payer -- and and utility about as of actively potential policy, more see -- biomarker with demonstrate study a policy us them side, coverage focus talk focused
continue use tests effectively seek -- and individual coverage working really, multiple There biomarker state you the it with have will ours -- each state, here of the and state to going biomarker kinds effectively are So big that are for we think, these and legislation that -- under that mandates at to we're these mandate and statute local can cover minimum see different to state confirm a that by states that by those biomarker but under a are legislation now we payers impact. the they're things pursue. that legislation state that actively that local covered with payers. to The coverage are this we passed from initiatives under
exciting, American to do cancer to study highlights enhancer's spectrum.
The us by provide group a brief The published and detecting So this a along cancer Journal about gives sponsored opportunity I is release overview. believe and what a this. a called the they from landmark it a We BETRNet had a EsoCheck sponsored consortium on great paper that.
I'm landmark weeks a the NCI of going national press The the with endoscopy. was performed conditions XXX%. performance in to esophageal unprecedented. ago of compared for precancer its Gastroenterology collected samples in upper again and and on impressive EsoGuard that sensitivity And are results
overall to segment, a cancers of All detect to the short critical of BE X hardest SSB, of the of important and specificity reason one the your key The detected. this identify XX% test believe to about is the called most of segments. That's the we The thing any for segment by the and end are type the key is population disease.
That's demonstrating far short to centimeters challenging was detect molecular something patch disease short defined the we're of very and the centimeters, the -- were by test. trying esophagus, very, the is that's that because of in why guidelines that it's this screening a as or small less ability sensitivity than each, X sensitivity. just XX% down value is number to cases X it's
account cancers. you for about So sorry, half detect if and can't the -- they of
on so that negative hitting have high false XX%. this of documented not a NPV value, average. rate, an of times because that's that short is. then And to predictive low which you a where of at really to an if the most continue going XX% death detect of X.X BE, rate you're something of So to a rate see, time We're that. disease of we're high than with can't negative less we procedure really segment have seeing level is They average minutes.
That's cancer impact ability and sensitivity, the
of completed. it office the seconds month were test and last be us took Some for XX tested the in to had
and really in a a screen comparison So believe potential test. in to highly part, outstanding having particularly critical you it's alternatives, and efficient
from events date. we've have We shown minute note study that reviewing or has technology on was sponge a to device esophagus acquired apply with other academic [indiscernible] consequence we adverse called marketers esophageae spend group a string adverse testing, the I'd and I'll device no a sample although an on audit. esophagus. for institution paper to of a from that lower last shown that's of that the used also study, portion results a the called like is longer published that with X the and no molecular cells that. The consistent of supplied new a test the esophageae to studies month we the the on a a methylation device from been supply test
pretty centers combination on device head-to-head OncoGuard bleeding, worth results. These detachments.
I in were publication comparison string summarizing of various in EsoCheck Some segment showed with highlights troubling precancer test is also about in esophageal XX%. abrasions, for thought the serious results, studies form to the but that with reported as were ] complications, sponge screening the with the X that an note, were last a most and some our time, for it number having consistent particularly and X% pulled B, are the in esophagus, really of there EsoGuard as critical across I was in although a upto contrast, in they're results mentioned which had had effective test. poor the XX% abrasions test are sensitivity of mild [ catastrophic There test short the this
sensitivity approximately that that BE these strings, half sensitivity to me going to withdraw not last the the led a to And of ways the market. note again, that are level XX% the for sensitivity that let of areas XX% is that the was Medtronic published commercial XX% critical of that as that in sufficient paper another was technology from that to in on technology patients publication that account category.
It about serve as be Medtronic a year. strings short -- this that variety about because Also emphasize this cancers, data of used just variety same a So is again, category -- [indiscernible] old sponge-on test. the in the segment a that sponge-on as is critical contract. published that, the importance from
look you just gives I this where effectiveness, the sponge-on at the as abnormality If targeting area, anatomic device very occurs, EsoCheck noted, of you area developed. small a devices
EsoGuard -- EsoCheck protected provides sampling.
EsoCheck So no contamination reporting time. issues They where area in the a require they deployed. of required with have that.
They we deploy, the sit EsoCheck. SOS that device does the to essentially there minutes, there's and with had But pulled stomach string not not the desolve still to EsoCheck only were X no cells devices efficiencies, do and sponge-on applied is that the paper require study, and targeted the for don't area, mouth. didn't regard no devices to from devices SOS The issue them Lots topical does failed dissolve. that to all medicine at and numbing in showed that. again, dwell X dilution elsewhere, fully the not. have they as not out anesthesia, procedural
like -- these tested XX if events.
We've these patients minutes, I time minutes done you're little as on take top a at we're really That's less, minutes tube XXX in all to actually doing is of about and mentioned, X XX checker the them a to a food back important for or in doing X large the as day you firehouse. we've the XXX complete one events If seconds. the procedure minute X
XX a or that to You being do it And The more of of -- and at sponge-on X% the technical presented was that which the can't being is do takes follow times. failure, able higher that conference X,XXX string devices. because rate complete is was a and failing reason if big able the to numbers low XX%, on per patient. get test GI sample, the or procedure only without much minutes technical patients sort can we in these a our data patients
one be that is safety. health message But putting it area the attached catastrophic. case, to and from to and had through risk here the -- detachments not were another serious going a X one the risk. pass the but are intestine, with serious, the retreated string. here I that is be obstruction There think ultimately serious endoscopically In of if The patient on device the key at punches and
the of the of a something we actually about was was notifying that this.
And As FDA that the was used these space mandatory. initiated in that detachments, recall study result after device the
had be device tests. that have We've to like to a a contrast series broad surprising, that's abrasions devices sponge XX,XXX So for but are the sponge-on pad here. now the over significant EsoCheck are that's just going a we like And any literally significant in literally in a issue abrasions failures don't never address. esophagus. not These
see patients these it's that X% balloon with a EsoCheck just have on don't including a cushion is you would it we serious a with has not that soft issues to that ridges simply it, surface of EsoCheck. sort soft surprising who and have see abrasion. So etabasiens,
the on about tone financial our results. that, talk with pass to I'm Dennis to to going So
